At the forefront of therapies for rare and orphan diseasesTM
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events

Home >> Investor Relations >> Investor Relations

Investor Relations

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.

View all »Recent Releases

Feb 3, 2016
Amicus Therapeutics to Present at the Leerink Partners 5th Annual Global Healthcare Conference

Jan 11, 2016
Amicus Therapeutics Provides Full-Year 2016 Strategic Outlook and Financial Guidance

View all »Events & Presentations

Jan 12, 2016 at 9:00 AM PT
34th Annual J.P. Morgan Healthcare Conference

Jan 10, 2016 at 12:35 PM PT
3rd Annual Dermatology Summit

Copyright © 2016 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy